 |
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).
- The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland...
Australia’s small business sector has launched a fierce campaign against the Reserve Bank of Australia’s (RBA) proposed ban on debit and credit card...
A new generation of young Australian small business owners is redefining success, driven by a desire to create a lasting legacy through the positi...
In a world where many small businesses are still trying to work out how to actually use AI (not just talk about it), Australian fintech LoanOption...
The world of mobility is changing fast, and car ownership is no longer the default. Across Australia, professionals and businesses alike are seeki...
“You shouldn’t need a large account balance to experience real-time investing. Technology should make that kind of access universal.” For decades...
Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, announced that Greg Nicolle, G...